Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28331243 | 0.92 | LMNA (0.34) | ATMPRMT1LMNATSHRADRA1A | |
| SCHEMBL20528884 | 0.82 | MAPK1 (0.40) | ATMPRMT1LMNATSHRADRA1A | |
| SCHEMBL22344974 | 0.81 | ATM (0.32) | ATMLMNATSHR | |
| SCHEMBL20528837 | 0.78 | ECE1 (0.36) | ATMLMNATSHRMAPK1KDM4E | |
| SCHEMBL1257927 | 0.77 | PRMT1 (0.63) | PRMT1LMNATSHRADRA1AMAPK1 | |
| SCHEMBL493520 | 0.77 | PRMT1 (0.63) | PRMT1LMNATSHRADRA1AMAPK1 | |
| SCHEMBL30905813 | 0.74 | PRMT1 (0.59) | PRMT1LMNATSHRADRA1AMAPK1 | |
| SCHEMBL20528878 | 0.74 | HPGD (0.32) | LMNA | |
| SCHEMBL964583 | 0.72 | ECE1 (0.58) | ATMPRMT1LMNATSHRKDM4E | |
| SCHEMBL2806091 | 0.70 | ATM (0.57) | ATMPRMT1LMNATSHRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11471537-B2 | Oligomer extended insulin-Fc conjugates | NOVO NORDISK A/S (DK) | 2022-10-18 | — | — | US | disclosed |
| US-20200261595-A1 | Oligomer Extended Insulin-FC Conjugates | NOVO NORDISK A/S (DK) | 2020-08-20 | — | — | US | disclosed |
| EP-3606560-A2 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES | Novo Nordisk A/S (DK) | 2020-02-12 | — | — | EP | disclosed |
| CN-110505885-A | Oligomer-extended insulin-Fc conjugates | NOVO NORDISK AS | 2019-11-26 | — | — | CN | disclosed |
| WO-2018185131-A2 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES | NOVO NORDISK A/S (DK) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261595-A1 | Oligomer Extended Insulin-FC Conjugates | IAPP, IDE, INSR | ATM 4253/4885PRMT1 3526/4885LMNA 4291/4885 |
| US-11471537-B2 | Oligomer extended insulin-Fc conjugates | IAPP, IDE, INSR | ATM 4253/4885PRMT1 3526/4885LMNA 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.